From: Roles of preoperative C-reactive protein are more relevant in buccal cancer than other subsites
Characteristic | CRP | p value | |||
---|---|---|---|---|---|
Negative | Positive | ||||
Pathologic tumor status | |||||
 Early (T1–T2) (n = 43) | 38 | (88.4%) | 5 | (11.6%) | 0.001 |
 Advanced (T3–T4) (n = 42) | 24 | (57.1%) | 18 | (42.9%) |  |
Pathologic N stage | |||||
 N0 (n = 54) | 40 | (74.1%) | 14 | (25.9%) | 0.277 |
 N1 (n = 14) | 8 | (57.1%) | 6 | (42.9%) | 0.765a |
 N2 (n = 17) | 14 | (82.4%) | 3 | (17.6%) |  |
Nodal status | |||||
 (−) metastasis, (−) ECS (n = 54) | 40 | (74.1%) | 14 | (25.9%) | 0.915 |
 (+) metastasis, (−) ECS (n = 15) | 11 | (73.3%) | 4 | (26.7%) | 0.694a |
 (+) metastasis, (+) ECS (n = 16) | 11 | (68.8%) | 5 | (31.2%) |  |
Differentiation | |||||
 Well (n = 26) | 21 | (80.8%) | 5 | (19.2%) | 0.425 |
 Moderate (n = 49) | 35 | (71.4%) | 14 | (28.6%) | 0.195a |
 Poor (n = 10) | 6 | (60.0%) | 4 | (40.0%) |  |
Tumor stage | |||||
 Early (I–II) (n = 30) | 27 | (90.0%) | 3 | (10.0%) | 0.009 |
 Advanced (III–IV) (n = 55) | 35 | (63.6%) | 20 | (36.4%) |  |
Skin invasion | |||||
 No (n = 77) | 57 | (74.0%) | 20 | (26.0%) | 0.677a |
 Yes (n = 8) | 5 | (62.5%) | 3 | (37.5%) |  |
Nerve invasion | |||||
 No (n = 66) | 48 | (72.7%) | 18 | (27.3%) | 0.934 |
 Yes (n = 19) | 14 | (73.7%) | 5 | (26.3%) |  |
Blood vessel invasion | |||||
 No (n = 79) | 59 | (74.7%) | 20 | (25.3%) | 0.337a |
 Yes (n = 6) | 3 | (50.0%) | 3 | (50.0%) |  |
Lymphatic invasion | |||||
 No (n = 83) | 60 | (72.3%) | 23 | (27.7%) | 0.383 |
 Yes (n = 2) | 2 | (100.0%) | 0 | (0.0%) |  |
Tumor depth ≥10 mm | |||||
 No (n = 42) | 36 | (85.7%) | 6 | (14.3%) | 0.009 |
 Yes (n = 43) | 26 | (60.5%) | 17 | (39.5%) |  |
Bone invasion | |||||
 No (n = 54) | 47 | (87.0%) | 7 | (13.0%) | <0.001 |
 Yes (n = 31) | 15 | (48.4%) | 16 | (51.6%) |  |